Clinical Trial Update: A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation [Phase 2, Phase 3]

View source ↗

Summary

A combined Phase 2/3 trial evaluated buparlisib (BKM120) with paclitaxel in HER2-negative locally advanced or metastatic breast cancer, with or without PI3K act…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BKM120 (Buparlisib) (buparlisib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2017-01-27